Frequency of Health Care Resource Utilization and Direct Medical Costs Associated with Psoriatic Arthritis in a Rheumatic Care Center in Colombia

References

• ADAPTE Collaboration. The ADAPTE process: resource toolkit for guideline adaptation (version 2.0). Guidelines International Network, 2009.
   Google Scholar
• Elmamoun M, Eraso M, Anderson M, et al. International league of associations for rheumatology recommendations for the management of psoriatic arthritis in resource-poor settings. Clin Rheumatol. 2020;39(6):1839–1850. doi:10.1007/s10067-020-04934-7
   Web of Science ®Google Scholar
• Gladman DD, Antoni C, Mease P, Clegg DO, Nash O. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(suppl 2):ii14-ii17.
   Google Scholar
• Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol. 2001;28(8):1842–1846.
   PubMed Web of Science ®Google Scholar
• Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386(10012):2489–2498. doi:10.1016/S0140-6736(15)00347-5
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–970. doi:10.1056/NEJMra1505557
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016;3(1):91–102. doi:10.1007/s40744-016-0029-z
   PubMed Web of Science ®Google Scholar
• González S, Queiro R, Ballina J. Actualización en la patogenia de la artritis psoriásica [Update in the pathogenesis of psoriatic arthritis]. Reumatol Clin. 2012;8(SUPPL.1):1–6. Spanish. doi:10.1016/j.reuma.2011.12.003
   Google Scholar
• Fernández-Ávila DG, Beltrán A, González C, et al. Traducción y validación de la versión en español del cuestionario ToPAS (Toronto Psoriatic Arthritis Screening Questionnaire), para el tamizaje de pacientes con artritis psoriásica en la consulta dermatológica en Colombia [Translation and validation of the Spanish version of the ToPAS (Toronto Psoriatic Arthritis Screening) questionnaire for use on patients with psoriatic arthritis in Dermatology clinics in Colombia]. Rev Colomb Reumatol. 2017;24(2):79–83. Spanish.
   Google Scholar
• Dominguez-Rosado I, Moutinho V, Dematteo RP, Kingham TP, D’Angelica M, Brennan MF. Outcomes of the Memorial Sloan Kettering Cancer Center International General Surgical Oncology Fellowship. J Am Coll Surg. 2016;222(5):961–966. doi:10.1016/j.jamcollsurg.2016.01.049
   PubMed Web of Science ®Google Scholar
• Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):242–248. doi:10.1016/j.jaad.2015.05.001
   PubMed Web of Science ®Google Scholar
• Eder L, Haddad A, Rosen CF, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheumatol. 2016;68(4):915–923. doi:10.1002/art.39494
   PubMed Web of Science ®Google Scholar
• Ogdie A, Haynes K, Troxel AB, et al. Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. Ann Rheum Dis. 2014;73(1):149–153. doi:10.1136/annrheumdis-2012-202424
   Web of Science ®Google Scholar
• Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum. 1998;41(6):1103–1110. doi:10.1002/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N
   PubMed Web of Science ®Google Scholar
• Dai YX, Hsu MC, Hu HY, et al. The risk of mortality among psoriatic patients with varying severity: a nationwide population-based cohort study in Taiwan. Int J Environ Res Public Health. 2018;15(12):2622. doi:10.3390/ijerph15122622
   Web of Science ®Google Scholar
• Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68:1060–1071. doi:10.1002/art.39573
   Web of Science ®Google Scholar
• Gossec L, Smolen JS, Gaujoux-Viala C, et al. European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4–12. doi:10.1136/annrheumdis-2011-200350
   PubMed Web of Science ®Google Scholar
• Kwan-Morley J, Marchetta P, Gladman DD, et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. J Psoriasis Psoriatic Arthritis. 2018;4(1). doi:10.1177/2475530318810851.
   Google Scholar
• Arokiasamy P, Uttamacharya KP, Capistrant BD, et al. Chronic noncommunicable diseases in 6 low- and middle-income countries: findings from wave 1 of the world health organization’s Study on Global Ageing and Adult Health (SAGE). Am J Epidemiol. 2017;185(6):414–428. doi:10.1093/aje/kww125
   PubMed Web of Science ®Google Scholar
• López-Estebaranz JL, Zarco-Montejo P, Escalas-Taberner J, García-Rodríguez M, García-Llorente JF, García-Calvo C. Clinical management of psoriatic arthritis in Spain: the CALIPSO study. Actas Dermosifiliogr. 2010;101(7):629–636. doi:10.1016/j.ad.2010.03.006
   Google Scholar
• Maese J, Díaz Del Campo P, Seoane-Mato D, Guerra M, Cañete JD. Eficacia de los fármacos antirreumáticos modificadores de la enfermedad sintéticos en artritis psoriásica: una revisión sistemática. Reumatol Clin. 2018;14(2):81–89. doi:10.1016/j.reuma.2016.10.005
   PubMed Web of Science ®Google Scholar
• Sociedad Española de Reumatología. ESPOGUÍA: Guía de Práctica Clínica para el Tratamiento de la Espondiloartritis Axial y la Artritis Psoriásica [ESPOGUÍA: Clinical Practice Guide for the Treatment of Axial Spondyloarthritis and Psoriatic Arthritis]. Madrid; 2018. Spanish.
   Google Scholar
• Ministerio de Salud y Protección Social [Ministry of Health and Social Protection]. Comportamiento del aseguramiento [Assurance behavior]; 2018 [ cited May 21, 2020]. Available from: https://www.minsalud.gov.co/proteccionsocial/Regimensubsidiado/Paginas/coberturas-del-regimen-subsidiado.aspx. Accessed February 9, 2021. Spanish.
   Google Scholar
• Guerrero R, Isabel Gallego A, Becerril-Montekio, V, Vásquez, J. Sistema de salud de Colombia [The health system of Colombia]. Salud Pública de México. 2011;53:s144-155. Spanish.
   Google Scholar
• Instituto Nacional de Salud - Observatorio Nacional de Salud [National Institute of Health - National Health Observatory]. Acceso a servicios de salud en Colombia [Access to health services in Colombia]. Bogotá, DC: Decimo Prim Inf Tecnico; 2019. Spanish.
   Google Scholar
• Congi L, Roussou E. Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria. Clin Exp Rheumatol. 2010;28(3):304–310.
   PubMed Web of Science ®Google Scholar
• Instituto de Evaluación Tecnológica en Salud-IETS [Institute of Technological Evaluation in Health]. Manual para la elaboración de evaluaciones económicas en salud [Manual for the preparation of economic evaluations in health]. Bogotá, Colombia: Instituto de Evaluación Tecnológica en Salud; 2014. Spanish.
   Google Scholar
• SISPRO. Sistema Integral de Información de la Protección Social [Comprehensive Social Protection Information System]. Spanish. Available from: https://web.sispro.gov.co/WebPublico/Consultas/ConsultarCNPMCadenaComercializacionCircu2yPA_028_2_2.aspx. Accessed April 2020.
   Google Scholar
• Ministerio de Salud y Protección Social [Ministry of Health and Social Protection]. Acuerdo No. 256 de 2001 - Manual de Tarifas de la Entidad Promotora de Salud del Seguro Social; 2001 [Agreement No. 256 of 2001 - Rate Manual of the Social Security Health Promotion Entity; 2001]. Spanish. Available from: https://miscuentasmedicas.com/manual-iss-2001.
   Google Scholar
• Instituto de Evaluación Tecnológica en Salud [Institute of Technological Evaluation in Health]. Qué es el IETS; 2018 [What is the IETS; 2018]. Spanish. Available from: https://www.iets.org.co/IETS/IETS.aspx.
   Google Scholar
• Banco de la República de Colombia [Bank of the Republic of Colombia]. Tasa de cambio representativa del mercado - Serie histórica de periodicidad mensual [Market representative exchange rate - Historical series of monthly periodicity]. Bogotá D.C.; 2020. Spanish. Available from: https://www.banrep.gov.co/es/estadisticas/trm.
   Google Scholar
• Nachar N. The Mann-Whitney U: a test for assessing whether two independent samples come from the same distribution. Tutor Quant Methods Psychol. 2008;4(1):13–20. doi:10.20982/tqmp.04.1.p013
   Google Scholar
• Dodd S, Bassi A, Bodger K, Williamson P. A comparison of multivariable regression models to analyse cost data. J Eval Clin Pract. 2006;12(1):76–86. doi:10.1111/j.1365-2753.2006.00610.x
   PubMed Web of Science ®Google Scholar
• Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy. 2004;9(4):197–204. doi:10.1258/1355819042250249
   PubMedGoogle Scholar
• Ministerio de Salud [Ministry of Health]. Resolución No. 8430 de 1993 [Resolution No. 8430 of 1993]; 1993 [ cited November 13¸ 2019]. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/RESOLUCION-8430-DE-1993.PDF. Accessed February 9, 2021. Spanish.
   Google Scholar
• González-Vacarezza N, Bertoldi EG, Deminco A, González G, Martínez Asuaga M. Análisis Costo-Utilidad Del Uso De Adalimumab, Etanercept E Infliximab Para El Tratamiento De La Artritis Psoriásica En Uruguay [Cost-Utility Analysis of the Use of Adalimumab, Etanercept and Infliximab for the Treatment of Psoriatic Arthritis in Uruguay]. Value Health Reg Issues. 2014;5:58–64. Spanish. doi:10.1016/j.vhri.2014.09.001
   Google Scholar
• Lopes N, Dias LLS, Azulay-Abulafia L, et al. Humanistic and economic impact of moderate to severe plaque psoriasis in Brazil. Adv Ther. 2019;36(10):2849–2865. doi:10.1007/s12325-019-01049-7
   Web of Science ®Google Scholar
• Merola JF, Herrera V, Palmer JB. Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA. Clin Rheumatol. 2018;37(10):2751–2761. doi:10.1007/s10067-018-4187-y
   PubMed Web of Science ®Google Scholar
• Burgos-Pol R, Martínez-Sesmero JM, Ventura-Cerdá JM, Elías I, Caloto MT, Casado M. Coste de la psoriasis y artritis psoriásica en cinco países de Europa: Una revisión sistemática [The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review]. Actas Dermosifiliogr. 2016;107(7):577–590. Spanish. doi:10.1016/j.ad.2016.04.018
   PubMed Web of Science ®Google Scholar
• Mora C, González A, Díaz J, Quintana G. Costos directos de la artritis reumatoide temprana en el primer año de atención: simulación de tres situaciones clínicas en un hospital universitario de tercer nivel en Colombia [Direct costs of early rheumatoid arthritis in the first year of care: simulation of three clinical situations in a tertiary university hospital in Colombia]. Biomedica. 2009;29(1):43–50. Spanish. doi:10.7705/biomedica.v29i1.40
   Web of Science ®Google Scholar
• McHugh N, Maguire Á, Handel I, et al. Evaluation of the economic burden of psoriatic arthritis and the relationship between functional status and healthcare costs. J Rheumatol. 2019;47(5):701-707.
   Web of Science ®Google Scholar
• Montoya N, Gómez L, Vélez M, Rosselli D. Costos directos del tratamiento de pacientes con artritis reumatoide en Medellín, Colombia. Rev Colomb Reumatol. 2011;18(1):26–33.
   Google Scholar
• Zhu B, Edson-Heredia E, Gatz JL, Guo J, Shuler CL. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study. Clin Ther. 2013;35(9):1376–1385. doi:10.1016/j.clinthera.2013.07.328
   PubMed Web of Science ®Google Scholar
• Santos-Moreno P, Alvis-Zakzuk NJ, Villarreal-Peralta L, Carrasquilla-Sotomayor M, Paternina-Caicedo A, Alvis-Guzmán N. A comprehensive care program achieves high remission rates in rheumatoid arthritis in a middle-income setting. Experience of a Center of Excellence in Colombia. Rheumatol Int. 2018;38(3):499–505. doi:10.1007/s00296-017-3903-2
   Web of Science ®Google Scholar
• Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 2006;65(9):1175–1183. doi:10.1136/ard.2005.046367
   PubMed Web of Science ®Google Scholar
• Brodszky V, Bálint P, Géher P, et al. Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol Int. 2009;30(2):199–205. doi:10.1007/s00296-009-0936-1
   PubMed Web of Science ®Google Scholar
• Poole CD, Lebmeier M, Ara R, Rafia R, Currie CJ. Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK. Rheumatology. 2010;49(10):1949–1956. doi:10.1093/rheumatology/keq182
   PubMed Web of Science ®Google Scholar